{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T15:49:24Z","timestamp":1765295364757,"version":"3.41.2"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T00:00:00Z","timestamp":1678147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014382","name":"Ipsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Follicular lymphoma (FL) is the second most common lymphoma in the United States and is characterized by a variable clinical course, disease heterogeneity, and a relapse-and-remittance pattern historically accompanied by successive shortening of clinical response with every line of treatment. Factors such as progression of disease within 24 months of initial treatment are associated with poor survival outcomes. Although rituximab-based regimens are preferred for early lines of treatment, no clear standard of care exists for treatment of FL in the third-line setting or later as approved third-line treatments have not been compared in a prospective, randomized clinical trial. Rather, physicians may choose from several therapeutic classes with different safety profiles and dosing regimens, with consideration of patient and disease factors. Here we describe 2 hypothetical patients with relapsing or remitting FL, an elderly patient with comorbidities, and a younger patient whose FL progressed within 24 months. These cases are used to highlight key factors that clinicians should consider when selecting therapies for relapsed or refractory FL, such as patient frailty, age, comorbidities, as well as quality of life and patient-specific preferences for less intrusive treatment regimens or longer remission times.<\/jats:p>","DOI":"10.3389\/fonc.2023.1120358","type":"journal-article","created":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T06:18:45Z","timestamp":1678169925000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Treatment selection for patients with relapsed or refractory follicular lymphoma"],"prefix":"10.3389","volume":"13","author":[{"given":"Alan Z.","family":"Skarbnik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krish","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,7]]},"reference":[{"key":"B1","unstructured":"Lymphoma - non-Hodgkin: Subtypes2019"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21037\/aol-21-5","article-title":"Genetic heterogeneity in follicular lymphoma","volume":"5","author":"Perrett","year":"2021","journal-title":"Ann Lymphoma"},{"key":"B3","unstructured":"SEER cancer stat facts: NHL \u2014 follicular lymphoma2021"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.03.3696","article-title":"Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at the University of Texas M.D. Anderson Cancer Center","volume":"24","author":"Liu","year":"2006","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-491514","article-title":"Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience","volume":"122","author":"Tan","year":"2013","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.annonc.2020.11.008","article-title":"Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dreyling","year":"2021","journal-title":"Ann Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.36469\/001c.38070","article-title":"Treatment patterns of follicular lymphoma in the united states: a claims analysis","volume":"9","author":"Huntington","year":"2022","journal-title":"J Health Econ Outcomes Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/jco.18.00605","article-title":"First-line treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus r-CHOP or r-CVP: results of the BRIGHT 5-year follow-up study","volume":"37","author":"Flinn","year":"2019","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or r-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2020000156","article-title":"How do I sequence therapy for follicular lymphoma","volume":"2020","author":"Salles","year":"2020","journal-title":"Hematology"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805104","article-title":"Rituximab plus lenalidomide in advanced untreated follicular lymphoma","volume":"379","author":"Morschhauser","year":"2018","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020010263","article-title":"Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials","volume":"139","author":"Casulo","year":"2022","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx189","article-title":"Unmet needs in the first-line treatment of follicular lymphoma","volume":"28","author":"Casulo","year":"2017","journal-title":"Ann Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/hon.75_2629","article-title":"AUGMENT phase III study: lenalidomide\/rituximab (r2) improved efficacy over rituximab\/placebo in relapsed\/refractory follicular patients irrespective of POD24 status [abstract 069]","volume":"37","author":"Leonard","year":"2019","journal-title":"Hematol Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-136834","article-title":"Primary analysis of ZUMA-5: a phase 2 study of axicabtagene ciloleucel (axi-cel) in patients with relapsed\/refractory (R\/R) indolent non-Hodgkin lymphoma (iNHL) [abstract]","volume":"136","author":"Jacobson","year":"2020","journal-title":"Blood"},{"volume-title":"Yescarta","year":"2022","key":"B16"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.00010","article-title":"AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma","volume":"37","author":"Leonard","year":"2019","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41408-020-00340-z","article-title":"Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups","volume":"10","author":"Batlevi","year":"2020","journal-title":"Blood Cancer J"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15708","article-title":"Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era","volume":"184","author":"Rivas-Delgado","year":"2019","journal-title":"Br J Haematol"},{"volume-title":"Aliqopa","year":"2021","key":"B20"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.75.4648","article-title":"Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma","volume":"35","author":"Dreyling","year":"2017","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00145-5","article-title":"Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"22","author":"Matasar","year":"2021","journal-title":"Lancet Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30441-1","article-title":"Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial","volume":"21","author":"Morschhauser","year":"2020","journal-title":"Lancet Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1182\/blood-2019-123742","article-title":"Mosunetuzumab induces complete remissions in poor prognosis non-Hodgkin lymphoma patients, including those who are resistant to or relapsing after chimeric antigen receptor T-cell (CAR-T) therapies, and is active in treatment through multiple lines [abstract]","volume":"134","author":"Schuster","year":"2019","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-135839","article-title":"Mosunetuzumab shows promising efficacy in patients with multiply relapsed follicular lymphoma: updated clinical experience from a phase I dose-escalation trial [abstract]","volume":"136","author":"Assouline","year":"2020","journal-title":"Blood"},{"key":"B26","article-title":"Promising tolerability and efficacy results from dose-escalation in an ongoing phase IB\/II study of mosunetuzumab with polatuzumab vedotin for relapsed\/refractory b-cell non-Hodgkin\u2019s lymphoma [abstract S222]","volume":"5","author":"Ghosh","year":"2021","journal-title":"Hemasphere"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25711","article-title":"Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study","volume":"95","author":"Dreyling","year":"2019","journal-title":"Am J Hematol"},{"key":"B28","unstructured":"AmsterdamEuropean Medicines Agency2022"},{"journal-title":"Paper presented at: Annual Meeting and Exposition of the American Society of Hematology","year":"2021","author":"Neelapu","key":"B29"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01838-z","article-title":"Access to chimeric antigen receptor T cell therapy for diffuse large B cell lymphoma","volume":"38","author":"Snyder","year":"2021","journal-title":"Adv Ther"},{"volume-title":"Tazverik","year":"2020","key":"B31"},{"key":"B32","unstructured":"AmsterdamEuropean Medicines AgencyLunsumio2022"},{"volume-title":"Lunsumio","year":"2022","key":"B33"},{"key":"B34","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1182\/blood-2021-148778","article-title":"Glofitamab as monotherapy and in combination with obinutuzumab induces high complete response rates in patients (pts) with multiple relapsed or refractory (R\/R) follicular lymphoma (FL) [abstract 623]","volume":"138","author":"Morschhauser","year":"2021","journal-title":"Blood"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1120358\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T06:18:54Z","timestamp":1678169934000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1120358\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,7]]},"references-count":34,"alternative-id":["10.3389\/fonc.2023.1120358"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1120358","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2023,3,7]]},"article-number":"1120358"}}